Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05318027 · ClinicalTrials.gov registry record · Phase 2

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

A Phase 2 study of Lung Cancer and Head and Neck Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
1
Study location

NCT05318027: Recruiting Phase 2 study of Lung Cancer and Head and Neck Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

NCT05318027 is a Phase 2 study of Lung Cancer and Head and Neck Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05318027, a Phase 2 study of Lung Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Primary Outcome

Difference between Poisson event rates of triage visits between intervention and control arms

Interventions

  • DEVICE ChatBot

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-05-22
Est. Completion 2025-12
Phase Phase 2

What NCT05318027 shows while recruiting

NCT05318027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ChatBot is the first listed.

NCT05318027 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05318027 about?

NCT05318027 is a clinical study titled "ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy". Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage v...

What is the current status of trial NCT05318027?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-05-22. Estimated completion is 2025-12.

What conditions does trial NCT05318027 study?

This clinical trial studies the following conditions: Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer.

What interventions are being tested in trial NCT05318027?

The interventions under investigation include: ChatBot (DEVICE).

Who is sponsoring clinical trial NCT05318027?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05318027 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05318027's enrollment target sits among peer trials

70 224th of 409 higher than 182 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05318027, the US trial registry maintained by the National Library of Medicine. NCT05318027 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.